Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 88

Sort by

Sort Order Select

Journal Articles

Multimodal epigenetic microarray classifies AML, MDS and controls using peripheral blood

Miriam Neaman, Jasline Deek, Rita Haldar, Yakir Moshe, Moshe Mittelman, Irit Avivi, Amit Manor, Mika Bell, Roy Vitkon, Mor Levi, Karolis Sablauskas, Efstathios Kastritis, Tomas Papajik, Eva Kriegova, Yuval Ebenstein

Blood (2025) 146 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2025-3509

Published: 2025

Journal Articles

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Blood (2025) 146 (Supplement 1): 490.

https://doi.org/10.1182/blood-2025-490

Published: 2025

Journal Articles

ANKRD26-related thrombocytopenia: Hematologic malignancy characteristics, clinical outcomes, and precursor states

Blood (2025) 146 (Supplement 1): 1440.

https://doi.org/10.1182/blood-2025-1440

Published: 2025

Journal Articles

Non-invasive MDS diagnostic algorithm can also identify pre-MDS and distinguishes normal controls from MDS/pre-MDS patients without bone marrow examination

Howard Oster, Sandra Huber, Jacqueline Ferrari, Martina Boldini, Sara Pozzi, Chiara Elena, Catherine Cargo, Torsten Haferlach, Luca Malcovati, Moshe Mittelman

Blood (2025) 146 (Supplement 1): 5632.

https://doi.org/10.1182/blood-2025-5632

Published: 2025

Journal Articles

A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discovery

Marco Roncador, Elsa Bernard, Robert Hasserjian, Jacqueline Boultwood, Chiara Elena, Anna Gallì, Carmelo Gurnari, Cristina Mecucci, Lucienne Michaux, Moshe Mittelman, Martina Sarchi, Erica Travaglino, Donal P. McLornan, Seishi Ogawa, Elli Papaemmanuil, Eva Hellström Lindberg, Luca Malcovati, Mario Cazzola

Blood (2025) 146 (16): 1883–1896.

https://doi.org/10.1182/blood.2025028619

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

Blood (2025) 145 (18): 1987–2001.

https://doi.org/10.1182/blood.2024025131

Published: 2025

Includes: Supplemental data

Journal Articles

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 352.

https://doi.org/10.1182/blood-2024-203612

Published: 2024

Journal Articles

Targeted, Low Cost Epigenetic Microarray for AML and MDS Detection

Blood (2024) 144 (Supplement 1): 6142.

https://doi.org/10.1182/blood-2024-208540

Published: 2024

Journal Articles

Treatment Modalities and Outcomes of Multiple Myeloma Patients with Spinal Cord Compression: A Single Center Experience

Tamir Shragai, Yael Illouz, Natan Melamed, Svetlana Trestman, Moshe Mittelman, Inna Zetserov, Irit Mazza Avivi, Yael C. Cohen

Blood (2024) 144 (Supplement 1): 6932.

https://doi.org/10.1182/blood-2024-207068

Published: 2024

Journal Articles

A Phase 2B, Open-Label Multicenter Study of Tebapivat (AG-946), a Potent Pyruvate Kinase Activator, in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Amer M. Zeidan, Mikkael A. Sekeres, Hanny Al-Samkari, Hetty E. Carraway, Amy E. DeZern, Moshe Mittelman, Meredith Little, Vanessa Beynon, Xiaoshu Dai, Sal Sommakia, Jenny M. Despotovic, Parija Patel, Melissa Dibacco, Bruno Fattizzo, Eytan M. Stein, David Sallman, Austin G. Kulasekararaj, Uwe Platzbecker, Pierre Fenaux

Blood (2024) 144 (Supplement 1): 6708.

https://doi.org/10.1182/blood-2024-203073

Published: 2024

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Yael C. Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Moshe Mittelman, Inna Tzoran, Vladimir Vainstein, Noa Lowenton-Spier, Natan Melamed, Ella Krayzler, Ilana Pereg, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 2014.

https://doi.org/10.1182/blood-2023-185830

Published: 2023

Journal Articles

Do We Still Need to Perform Bone Marrow Examination in All Subjects Suspected of MDS? Evaluation and Validation of Non-Invasive (Web-Based) Algorithm

Howard S Oster, Ariel M Polakow, Noa Goldschmidt, Moshe Mittelman

Blood (2023) 142 (Supplement 1): 6475.

https://doi.org/10.1182/blood-2023-178713

Published: 2023

Journal Articles

Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn Study

Moshe Mittelman, David H. Henry, John Glaspy, Anil Tombak, Rosemary Anne Harrup, Krzysztof Madry, Barbara Grabowska, Uwe Platzbecker, Tyson Lee, Katharina Modelska

Blood (2023) 142 (Supplement 1): 195.

https://doi.org/10.1182/blood-2023-180749

Published: 2023

Journal Articles

Outcomes of Acute Myeloid Leukemia Patients Suffering from an Additional Active Malignancy Treated with Venetoclax and Azacitidine: A Single Center Experience

Yakir Moshe, Shai Levi, Miriam Neaman, Roi Gat, Mor Levi, Nili Eilati, Gil Fridberg, Yotam Bornstein, Tamir Shragai, Tsipora Neuman, Roy Vitkon, Eliya Shachar, David Sarid, Ofer Merimsky, Moshe Mittelman, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 5929.

https://doi.org/10.1182/blood-2023-186234

Published: 2023

Journal Articles

Yoga As Possible Non-Medical Intervention to Improve Quality of Life of Patients with Myelodysplastic Syndromes - a Feasibility Report

Irina Amitai, Ilana Hellmann, Maya Koren-Michowitz, Tsila Zuckerman, Ariel Aviv, Anatoly Nemets, Itai Levi, Yishai Ofran, Moshe Mittelman, Drorit Grizim Merkel

Blood (2022) 140 (Supplement 1): 12349–12350.

https://doi.org/10.1182/blood-2022-166542

Published: 2022

Journal Articles

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Blood (2022) 140 (Supplement 1): 9802–9803.

https://doi.org/10.1182/blood-2022-167716

Published: 2022

Journal Articles

Validation of a Novel Algorithm with a High Specificity in Ruling out MDS

Felicitas Schulz, Kathrin Nachtkamp, Howard S. Oster, Moshe Mittelman, Norbert Gattermann, Carmen Barthuber, Sarah Schweier, Ulrich Germing

Blood (2022) 140 (Supplement 1): 9789–9790.

https://doi.org/10.1182/blood-2022-163431

Published: 2022

Journal Articles

Can We Identify Individuals at Risk to Develop Multiple Myeloma? a Machine Learning Based Predictive Model

Moshe Mittelman, Howard S. Oster, Yatir Ben Shlomo, Ariel Israel, Osnat Jarchowcky Dolberg, Samah Hayek, Michael Leshchinsky, Eldad Kepten, Ran Balicer, Galit Shaham

Blood (2022) 140 (Supplement 1): 7259–7260.

https://doi.org/10.1182/blood-2022-162438

Published: 2022

Journal Articles

Erythropoietin Administration Delays B Cell Maturation and Promotes B Cell to Erythroid Transdifferentiation in Mice

Albert Kolomansky, Anton Gorodov, Stav Kislev, Nathalie Ben-Califa, Alana Starr, Yankel Gabet, Martina Rauner, Ben Wielockx, Moshe Mittelman, Howard S. Oster, Drorit Neumann

Blood (2022) 140 (Supplement 1): 1241–1242.

https://doi.org/10.1182/blood-2022-167848

Published: 2022

Journal Articles

Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting

Moshe Mittelman, Ori Magen, Noam Barda, Noa Dagan, Howard S. Oster, Avi Leader, Ran Balicer

Blood (2022) 139 (10): 1439–1451.

https://doi.org/10.1182/blood.2021013768

Published: 2022

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Multimodal epigenetic microarray classifies AML, MDS and controls using peripheral blood

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

ANKRD26-related thrombocytopenia: Hematologic malignancy characteristics, clinical outcomes, and precursor states

Non-invasive MDS diagnostic algorithm can also identify pre-MDS and distinguishes normal controls from MDS/pre-MDS patients without bone marrow examination

A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discovery

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Targeted, Low Cost Epigenetic Microarray for AML and MDS Detection

Treatment Modalities and Outcomes of Multiple Myeloma Patients with Spinal Cord Compression: A Single Center Experience

A Phase 2B, Open-Label Multicenter Study of Tebapivat (AG-946), a Potent Pyruvate Kinase Activator, in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Do We Still Need to Perform Bone Marrow Examination in All Subjects Suspected of MDS? Evaluation and Validation of Non-Invasive (Web-Based) Algorithm

Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn Study

Outcomes of Acute Myeloid Leukemia Patients Suffering from an Additional Active Malignancy Treated with Venetoclax and Azacitidine: A Single Center Experience

Yoga As Possible Non-Medical Intervention to Improve Quality of Life of Patients with Myelodysplastic Syndromes - a Feasibility Report

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Validation of a Novel Algorithm with a High Specificity in Ruling out MDS

Can We Identify Individuals at Risk to Develop Multiple Myeloma? a Machine Learning Based Predictive Model

Erythropoietin Administration Delays B Cell Maturation and Promotes B Cell to Erythroid Transdifferentiation in Mice

Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only